Filing Details
- Accession Number:
- 0001610717-23-000405
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-12-19 17:34:13
- Reporting Period:
- 2023-12-15
- Accepted Time:
- 2023-12-19 17:34:13
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1676725 | Ideaya Biosciences Inc. | IDYA | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1649119 | S Yujiro Hata | C/O Ideaya Biosciences, Inc. 7000 Shoreline Court, Suite 350 South San Francisco CA 94080 | President And Ceo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-12-15 | 75,000 | $4.31 | 752,887 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-12-15 | 75,000 | $35.03 | 677,887 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2023-12-15 | 75,000 | $0.00 | 75,000 | $4.31 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 399,454 | 2028-02-26 | No | 4 | M | Direct |
Footnotes
- The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 11, 2023.
- This transaction was executed in multiple trades in prices ranging from $35.00 to $35.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The shares subject to the option are fully vested and exercisable.
Billionaire Hedge Funds
